Lupin Limited's Board of Directors convened on May 07, 2026, and approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, pursuant to Regulation 33 of the SEBI Listing Regulations. Subsequently, on May 09, 2026, the Company filed a newspaper advertisement under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, disclosing an extract of the audited financial results. Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the Q4 FY26 Earnings Call — conducted through digital means on May 08, 2026 at 16:00 hrs (IST) — has been made available on the Company's website. The Board also recommended a dividend of ₹18/- (Rupees Eighteen only) per equity share of face value ₹2/- each, representing 900% of face value, aggregating ₹8,229.2 million. The dividend is subject to declaration by shareholders at the ensuing Annual General Meeting and shall be paid within 30 days from the date of such declaration. The statutory auditors, B S R & Co. LLP, Chartered Accountants, issued audit reports with unmodified opinions on both the standalone and consolidated financial results.

Analyst Views: CLSA, Nomura, and Morgan Stanley Bullish

Multiple brokerages have reaffirmed their positive stance on Lupin following the strong Q4 FY26 results. CLSA has maintained an Outperform rating with a target price of ₹2,690, citing an all-round Q4 FY26 beat led by strong US business, improved India profitability, and better operating efficiency. CLSA noted that management expects high-single to low-double-digit FY27 revenue growth and a 25% EBITDA margin, despite competition in key products and rising cost pressures, supported by strong India growth and 80 planned product launches. Nomura has maintained a Buy rating with a target price of ₹2,580, driven by strong Q4 FY26 sales/EBITDA/PAT growth of 33%/68%/89% YoY with sharp margin expansion and broad-based double-digit regional growth. Nomura noted that management guides for high-single-digit FY27 revenue growth and a 25% EBITDA margin, despite expected US competition in key products, supported by strong India and emerging market momentum. Morgan Stanley has maintained an Equal-weight rating with a target price of ₹2,386, citing a strong Q4 beat across revenue, EBITDA, and PAT, driven by robust US business performance, 11.5% year-on-year India growth, and 49% year-on-year emerging market growth, further aided by high-value gMyrbetriq and continued gSpiriva sales.

Management Commentary: FY27 Outlook and US Margin Headwinds

Lupin's management has guided for high-single to low-double-digit FY27 revenue growth and a 25% EBITDA margin, supported by strong India growth and 80 planned product launches. However, management has also flagged that the company could see negative headwinds on margins as far as the USA business is concerned, according to CNBC. This cautionary note comes even as the company delivered a strong quarterly performance, underscoring the potential near-term pressure on profitability from its key US market, with competition expected in key products alongside rising cost pressures.

Consolidated Financial Performance

Lupin delivered a strong performance on a consolidated basis for the year ended March 31, 2026. Total revenue from operations grew significantly compared to the prior year, driven by growth in the pharmaceuticals segment. The following table summarises the key consolidated income statement metrics:

For the quarter ended March 31, 2026, consolidated net profit rose to ₹14.6 billion from ₹7.73 billion in the corresponding prior-year quarter, while total revenue from operations reached ₹74.7 billion compared to ₹56.7 billion. On the profitability front, Q4 EBITDA surged to ₹24.8 billion from ₹13.21 billion in the same quarter of the prior year, with the EBITDA margin expanding sharply to 33.6% from 23.31%, reflecting improved operational efficiency. The table below highlights the key quarterly consolidated metrics:

Consolidated Earnings Per Share

Consolidated earnings per share (face value ₹2/- each) for the year ended March 31, 2026 are presented below:

Standalone Financial Performance

On a standalone basis, Lupin also reported strong growth for the year ended March 31, 2026. Total revenue from operations reached ₹195,126.6 million, compared to ₹169,675.0 million in the prior year. Standalone net profit after tax for the year was ₹63,665.6 million, up from ₹39,729.6 million. The following table provides a summary of key standalone financials:

Standalone basic EPS (after exceptional items) for the year ended March 31, 2026 stood at ₹139.38, compared to ₹87.10 in the prior year. Diluted EPS (after exceptional items) was ₹139.01 versus ₹86.79. For the quarter ended March 31, 2026, standalone total revenue from operations was ₹52,346.0 million and net profit after tax was ₹21,636.9 million.

Standalone Cash Flow Highlights

On a standalone basis, net cash flow from operating activities for the year ended March 31, 2026 was ₹55,398.5 million, compared to ₹24,446.5 million in the prior year. Cash and cash equivalents at the end of the year stood at ₹1,116.3 million, versus ₹3,418.0 million at the start of the year. Net cash used in investing activities was ₹(56,488.9) million, while net cash used in financing activities was ₹(1,211.3) million.

Segment Performance

The pharmaceuticals segment continued to be the dominant revenue contributor on a consolidated basis. Segment-wise revenue and results for the year ended March 31, 2026 are as follows:

The pharmaceuticals segment reported a segment result of ₹70,502.7 million for the year ended March 31, 2026, compared to ₹41,608.1 million in the prior year. The "Others" segment reported a loss of ₹1,777.2 million versus a loss of ₹1,458.1 million in the prior year.

Consolidated Balance Sheet Highlights

As at March 31, 2026, consolidated total assets stood at ₹383,648.3 million, compared to ₹292,048.8 million as at March 31, 2025. Total equity increased to ₹225,133.7 million from ₹172,943.5 million. Key balance sheet figures are summarised below:

Consolidated cash and cash equivalents as at March 31, 2026 stood at ₹41,677.3 million, significantly higher than ₹15,436.9 million at the end of the prior year. Net cash flow from operating activities for the year was ₹73,345.0 million, compared to ₹29,999.4 million in the prior year.

Notable Corporate Developments and Exceptional Items

Several significant corporate developments were disclosed alongside the financial results:

• Antitrust Litigation: The Group created a cumulative provision of ₹5,816.9 million (USD 65.8 million) related to antitrust litigation matters as at the year ended March 31, 2026. In April 2026, Lupin Pharmaceuticals, Inc. (LPI), a wholly owned subsidiary, settled one of the ongoing antitrust matters for ₹2,654.1 million (USD 30.0 million) without admission of liability or wrongdoing.
• Astellas Settlement: On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas related to Mirabegron ER Tablets (a generic version of Myrbetriq ER Tablets) in US markets. LPI paid ₹8,475.5 million (USD 90.0 million), comprising ₹7,110.8 million (USD 75.0 million) as Prepaid Option and ₹1,364.7 million (USD 15.0 million) as a one-time settlement payment.
• VISUfarma Acquisition: During the year ended March 31, 2026, Lupin, through its wholly owned subsidiary Nanomi B.V., Netherlands, entered into a definitive agreement to acquire 100% share capital of VISUfarma B.V., Netherlands. The acquisition was concluded on April 01, 2026, with total consideration of ₹20,902.7 million (Euro 192.8 million).
• Renascience Pharma Acquisition: Through Lupin Healthcare (UK) Limited, the Company acquired 100% equity share capital of Renascience Pharma Limited, U.K., for a consideration of ₹1,361.6 million (GBP 12.3 million). Fair value of intangibles acquired was ₹1,239.4 million, deferred tax liability ₹309.8 million, and goodwill ₹325.9 million.
• OTC and API R&D Business Transfer: During the year ended March 31, 2026, the Company transferred its Over the Counter (OTC) and API R&D business in India to its wholly owned subsidiaries Lupinlife Consumer Healthcare Limited and Lupin Manufacturing Solutions Limited respectively, on a slump sale basis for considerations of ₹8,200.0 million and ₹180.0 million, resulting in gains of ₹6,589.6 million and ₹37.2 million respectively.
• New Labour Codes: The Group recognised an incremental cost of ₹512.2 million during the quarter ended December 31, 2025 and year ended March 31, 2026, following the implementation of the New Labour Codes effective November 21, 2025.
• ESOP Allotment: During the quarter ended March 31, 2026, 380,305 equity shares (year to date 614,066) of ₹2/- each were allotted upon exercise of vested stock options under Lupin Employees Stock Option Plans, increasing paid-up equity share capital by ₹0.7 million (year to date ₹1.2 million) and securities premium account by ₹463.2 million (year to date ₹719.7 million).

Lupin has outlined a comprehensive financial and strategic roadmap for FY27, projecting US revenue to remain above $1 billion even as competitive pressures on key products are expected to weigh on performance. The pharmaceutical major is simultaneously targeting strong single-digit revenue growth and EBITDA margins of approximately 25% for the fiscal year, reflecting a balanced approach to near-term profitability and long-term pipeline investment.

FY27 Financial Targets

Lupin has provided detailed guidance on its financial expectations for FY27. The company projects its effective tax rate at 25% to 26%, attributing the uptick to reduced incentives. On the revenue front, US sales are expected to remain above $1 billion, though the company anticipates a possible high single-digit or low double-digit revenue decline in that market, driven primarily by competition for Tolvaptan and Mirabegron. New product launches and broader business growth are expected to help offset these losses.

The following table summarizes Lupin's key FY27 financial and operational targets:

Pipeline and Product Launch Strategy

As part of its near-to-medium-term strategy, Lupin has set a target of 15 or more ANDA (Abbreviated New Drug Application) filings, a critical indicator of pipeline strength in the US generics market. The company plans to launch over 20 products in FY27, with the stated objective of outperforming market growth through this expanded pipeline. Looking ahead to FY28, Lupin has identified key upcoming launches including Ranibizumab, Dulera, and a new dosage form of Apixaban, signaling continued momentum in its US product pipeline.

Complex Generics and Biosimilars: 2028–2031 Focus

Beyond the immediate fiscal year, Lupin has identified complex generics and biosimilars as key strategic focus areas for the 2028–2031 period. These segments are considered higher-value and higher-barrier categories within the generics industry, requiring advanced manufacturing capabilities and specialized scientific expertise. Biosimilars, in particular, represent a growing opportunity as several high-value biologics face patent expiries. The following table outlines the longer-term strategic parameters:

Strategic Outlook

Lupin's multi-year roadmap spans near-term financial discipline in FY27 — including managing competitive headwinds on Tolvaptan and Mirabegron while sustaining US revenues above $1 billion — through to a longer-horizon pivot toward complex generics and biosimilars by 2028–2031. The company's margin guidance of approximately 25% EBITDA, factoring in rising R&D expenditure and competitive pressures, reflects a deliberate investment in future growth. Together, these targets outline a comprehensive approach to sustaining and expanding the company's competitive positioning across geographies and product categories.